Pharmaceutical Profiling in Drug Discovery and Development
- Datum: 23 januari 2025, kl. 8.00 – 24 januari 2025, kl. 13.00
- Plats: Universitetsaulan
- Typ: Konferens
- Arrangör: Uppsala universitet, Nordic Pharma Train, SciLifeLab, UDOPP, SweDeliver & Nordic POP
- Kontaktperson: Md Shakhawath Hossain
- Forskningsutmaning: Läkemedelsutveckling
Välkommen till Uppsala universitets symposium Pharmaceutical Profiling in Drug Discovery and Development. Denna 13:e upplaga sätter fokus på tillförsel och disposition av läkemedel, behandlingar och strategier inklusive Artificiell Intelligens och Maskinlärning i upptäckt och utveckling av läkemedel.
Symposiet uppmärksammar också Per Artursson, professor och chef vid SciLifeLabs DDD-plattform, och hans enastående forskargärning.
Anmälan senast 20 december på https://doit.medfarm.uu.se/bin/kurt3/kurt/8877640
Program 23 januari
08:00–08:45 Registration
08:45–08:55 Welcome Talk, Christel Bergström, Uppsala University, Sweden
Session 1: Chair: Pär Matsson, University of Gothenburg, Sweden
08:55–09:35 Kathy Giacomini, University of California San Francisco, USA
09:35–09:55 Madlen Hubert, Uppsala University, Sweden
3D human intestinal organoids: a predictive screening tool for oral drug delivery
09:55–10.25 Coffee break and poster mounting:
Session 2: Chair: Andre Mateus, Umeå University, Sweden
10:25–11:05 Kim Brouwer, UNC Eshelman School of Pharmacy, USA
Opportunities and Challenges in Predicting Hepatic Transporter-mediated Changes in Drug Disposition, Efficacy and Safety in Patients with MASLD
11:05–11:45 Volker Lauschke, Karolinska Institutet (KI), Sweden
Organotypic and microphysiological model systems for translational pharmacology
11:45–12:00 Evgeniya Mickols, Uppsala University
Evaluation and elevation of 3D primary human hepatocyte spheroids
12:00–13.00 Lunch break
Session 3: Chair: Alexandra Teleki, Uppsala University, Sweden
13:00–13:40 David Brayden, University College Dublin, Ireland
Formulation approaches to improve oral delivery of peptides-an update
13:40–14:20 Mike Hann, former GlaxoSmithKline, UK
Molecular Accessibility - Lessons in Transcellular Membrane Transport re-learned
14:20–14:35 Alina Meyer, Uppsala University
Target identification for drug repurposing in polycystic kidney disease
14:35–15.45 Coffee break and poster session
Session 4: Chair: Pawel Baranczewski, Uppsala University, Sweden
15:45–16:25 Thomas Helleday, Karolinska Institutet (KI), Sweden
16:25–16:45 Kristian Sandberg, ScilLifeLab DDD, Uppsala University, Sweden
Rewiring of SciLifeLab DDD to target the undruggable
16:45–17:05 Annika Jenmalm Jensen, ScilLifeLab, KI, Sweden
From Inception to Impact: The Story of CBCS
17:05–17:15 Pawel Baranczewski, ScilLifeLab DDD, Uppsala University, Sweden
The impact of UDOPP on Swedish academic drug discovery
Program 24 januari
Session 5: Chair: Christel Bergström, Uppsala University, Sweden
09:00–09:40 Wojciech Chrzanowski, University of Sydney, Australia
09:40–09:55 Prosper Emeh, Uppsala University
Effect of peptide lipidation, chemical structure and formulation on luminal stability and intestinal absorption
09:55–11.00 Coffee break and poster session
Session 6: Chair: Per Larsson, Uppsala University, Sweden
11:00–11:30 Sibylle Neuhoff, Certara UK Ltd.
Hepatic transporter-mediated DDIs assessed via PBPK modelling
11:30–11:50 Pär Matsson, University of Gothenburg, Sweden
Cellular exposure of new-modality therapeutics
11:50–12:10 André Mateus, Umeå University, Sweden
Gut bugs on sugars and drugs
12:10–12:30 Christel Bergström, Uppsala University, Sweden
Contemporary models and pharmaceutical production – from a virtual intestine to 3D printed medicines
12:30–13:00 Closing remark and take away lunch